10-Q: Organon & Co. Q3 2026: Sun Pharma Deal Progresses Amidst Mixed Sales

Organon & Co. reported Q3 2026 results showing slight revenue decline, progress on the Sun Pharma acquisition, and mixed performance across its product portfolio, with notable growth in Hadlima and Emgality.

Summary

• Organon & Co. reported Q3 2026 revenues of $1.574 billion, a 2% decrease from $1.602 billion in Q3 2025. For the nine months ended September 30, 2026, revenues were $4.592 billion, down 2% from $4.709 billion in the prior year.
• The company is progressing towards its acquisition by Sun Pharmaceutical Industries Limited, with stockholder approval received and an expected closing by early 2027.
• Key product areas showed varied performance: Womens Health revenue decreased by 2% for the quarter, driven by lower Nexplanon sales. General Medicines saw a 35% increase in Hadlima sales, but a significant 77% decrease in Ontruzant sales.
• Established Brands experienced mixed results, with Emgality sales up 16% and Vtama up 21% for the quarter, while cardiovascular and respiratory segments showed declines.
• Restructuring costs of $31 million were incurred in Q1 2026 related to R&D and manufacturing optimization.
• The company reported net income of $164 million for Q3 2026, up from $160 million in Q3 2025, and $418 million for the nine months, up from $392 million.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive, reflecting a stable financial performance and strategic progress, though tempered by ongoing litigation and market challenges.

Positives

• Net income increased to $164 million in Q3 2026 from $160 million in Q3 2025, and to $418 million for the nine months from $392 million.
• Hadlima sales increased by 35% for the quarter and 45% for the nine months, driven by stronger demand in the US and Puerto Rico.
• Emgality sales increased by 16% for the quarter and 33% for the nine months due to increased international demand.
• Vtama sales increased by 21% for the quarter and 15% for the nine months.
• The acquisition by Sun Pharma has received stockholder approval, with an expected closing by early 2027.
• Cash and cash equivalents increased significantly to $1.455 billion as of September 30, 2026, from $574 million at the end of 2025.
• Working capital improved to $2.72 billion from $1.96 billion.

Negatives

• Total revenues decreased by 2% for both the three and nine-month periods ended September 30, 2026, compared to the prior year.
• Nexplanon sales declined 10% for the quarter and 11% for the nine months, primarily due to decreased physician demand in the US and uncertainty around federal funding.
• Ontruzant sales declined significantly by 77% for both periods due to lower tendered volume from Brazil's Ministry of Health.
• Singulair sales declined 15% for the quarter and 31% for the nine months due to decreased demand and price reductions in international markets.
• The company faces ongoing litigation, including product liability lawsuits related to Fosamax and Nexplanon/Implanon, and securities and stockholder derivative litigation.
• Supply chain disruptions impacted certain Established Brands products, leading to an estimated revenue impact of less than 2% for the periods.

Risks

• The proposed acquisition by Sun Pharma is subject to customary closing conditions, including regulatory approvals, and may not be completed on anticipated terms or at all.
• The pendency of the Sun Pharma transaction could impact the company's ability to retain key personnel and maintain business relationships.
• Ongoing litigation, including product liability claims and securities litigation, could result in significant costs and potential liabilities.
• Loss of market exclusivity for certain products and competition from generic alternatives pose a continuous risk.
• Supply chain disruptions, manufacturing issues, and geopolitical events could impact product availability and increase costs.
• Changes in U.S. and foreign government laws and regulations, including pricing and reimbursement policies, could adversely affect business.
• The company faces risks related to cyberattacks and data privacy issues.

Future Outlook

The company expects the acquisition by Sun Pharma to close by early 2027. Volume-based procurement in China is expected to continue negatively impacting the general medicines product portfolio for the next several quarters. Management is implementing strategies to adapt to changing market conditions, including product discount programs and wholesaler inventory adjustments.

Management Comments

• The company is continuing to work with Sun Pharma to satisfy the conditions for closing the acquisition.
• Management is implementing mitigation strategies to improve production and supplier reliability and strengthen supply chain resilience.
• The company expects to continue incurring costs associated with separating its supply chain from Merck through planned exits from supply agreements.

Industry Context

StockSavvy.ai notes that Organon's performance reflects broader trends in the pharmaceutical industry, including the increasing importance of biosimilars, the challenges of supply chain disruptions, and the ongoing consolidation through mergers and acquisitions.

Comparison to Industry Standards

• Organon's revenue decline of 2% for the nine months is slightly worse than the projected modest growth for the global pharmaceutical market in 2026, which is estimated to be around 1-3% by various industry reports.
• The company's investment in biosimilars like Hadlima, which shows strong growth (45% YTD), aligns with the industry trend of expanding biosimilar portfolios to capture market share from high-cost biologics.
• The decline in Nexplanon sales due to physician demand and funding uncertainty highlights the sensitivity of the women's health market to healthcare policy and access issues, a factor impacting various therapeutic areas.
• The ongoing litigation, particularly product liability cases, is a common challenge for pharmaceutical companies, with Organon's approach to settlement and defense being a critical factor in managing these risks, similar to practices seen at companies like Pfizer and Merck in their respective litigation matters.

Legal Proceedings

• Product liability lawsuits involving Fosamax (alendronate sodium) alleging femur fractures and other bone injuries.
• Lawsuits relating to the use of Nexplanon and Implanon (etonogestrel implant) alleging various injuries.
• Securities class action lawsuits alleging materially false and misleading statements regarding capital allocation and debt reduction strategies.
• Stockholder derivative lawsuits asserting breach of fiduciary duties related to alleged misleading statements.
• Governmental inquiries and potential proceedings, including an SEC investigation into Nexplanon sales to certain wholesalers.
• Patent litigation against generic manufacturers seeking to market generic versions of Nexplanon and Vtama prior to patent expiration.

Related Party Transactions

• Manufacturing and supply agreements with Merck & Co., Inc. under the Separation and Distribution Agreement, with amounts due from and to Merck disclosed.

Stakeholder Impact

• Shareholders: The pending acquisition by Sun Pharma at $14.00 per share provides a clear exit valuation, though the closing is subject to conditions.
• Employees: Approximately 100 employees transferred to Laborie as part of the Jada divestiture; restructuring initiatives involved a headcount reduction.
• Customers/Suppliers: Supply chain disruptions have impacted availability and potentially customer demand for certain products; ongoing separation from Merck supply agreements will redefine sourcing strategies.
• Creditors: The company is in compliance with its senior credit agreement financial covenants.

Next Steps

• Continue working towards the closing of the Sun Pharma acquisition, expected by early 2027.
• Implement strategies to improve supply chain resilience and production reliability.
• Manage ongoing litigation and regulatory matters.
• Continue to adapt business and sales strategies to changing market conditions.
• Launch Epyztek in Australia in the first half of 2027.
• Commercialize Miudella in the United States in late 2026.

Key Dates

Recommendation

The company is in a transitional phase with a pending acquisition by Sun Pharma at a fixed price, which limits upside potential but provides a floor. While sales are mixed and litigation risks persist, the core business shows resilience in certain segments, and the acquisition offers a clear path forward. A 'hold' recommendation reflects the balance between these factors, awaiting the completion of the acquisition and post-transaction strategic clarity.

Keywords

Organon, Form 10-Q, Quarterly Report, Pharmaceuticals, Womens Health, Biosimilars, General Medicines, Sun Pharma Acquisition